Zhitong Finance App News, Shiyao Group (01093.HK) announced that the phase I clinical trial of SYS6063 developed by the group to treat recurrent refractory systemic lupus erythematosus (SLE) has been officially launched at the first center in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.